RENESSANS — Competitive Intelligence Brief

RENESSANS (RENESSANS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic. Area: Cardiovascular.

phase 3 Antiarrhythmic Unknown Cardiovascular Biologic

Target snapshot

RENESSANS (RENESSANS) — MTI Medical Private Limited, Pakistan. RENESSANS is a medication used to treat atrial fibrillation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RENESSANS TARGET	RENESSANS	MTI Medical Private Limited, Pakistan	phase 3	Antiarrhythmic	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Pf-08032562	pf-08032562	Pfizer Inc.	marketed	unknown	unknown
Optimized Treatment (OPT)	Optimized Treatment (OPT)	Second Affiliated Hospital of Wenzhou Medical University	marketed	Small molecule	Unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Antiarrhythmic class)

1. Pfizer · 3 drugs in this class
2. National Taiwan University Hospital · 2 drugs in this class
3. Boehringer Ingelheim · 1 drug in this class
4. Cliniques universitaires Saint-Luc- Université Catholique de Louvain · 1 drug in this class
5. Eli Lilly · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Technical University of Munich · 1 drug in this class
8. · 1 drug in this class
9. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class
10. Ain Shams University · 1 drug in this class